Gus Attridge’s stake in Africa’s largest pharma company drops by $16.5 million
South African pharma mogul Gus Attridge loses $16.5 million from stake in Africa’s largest pharmaceutical company.
South African pharma mogul Gus Attridge loses $16.5 million from stake in Africa’s largest pharmaceutical company.
Attridge, who serves as the group’s chief advisor, holds a 4.3-percent stake in the Durban-based pharmaceutical giant, amounting to 19,033,829 shares.
This follows a $12 million gain recorded between April 23 and May 3, when his stake rose from R4.07 billion ($219.65 million) to R4.29 billion ($231.65 million).
Attridge, Aspen’s group chief advisor, and a JSE heavyweight, holds a 4.3-percent stake in the pharmaceutical company, amounting to 19,033,829 ordinary shares.
The latest bump in his fortune comes on the heels of previous gains between Feb. 12 and March 24, when his stake in Aspen grew by R447.12 million ($25.12 million).
Attridge’s recent financial triumph is attributed to the recent surge in Aspen Pharmacare’s shares on the Johannesburg Stock Exchange (JSE).
Attridge, Aspen’s group chief advisor who ranks as one of South Africa’s richest businessmen, owns a 4.26-percent stake in the pharmaceutical holding company.
Attridge, Aspen’s group chief advisor who ranks as one of JSE’s richest investors, owns a 4.26-percent stake in the pharma group.
The upswing comes on the heels of a setback that led to Attridge recording a loss of $11.96 million between Oct. 2 and Oct. 26.
At the helm of Aspen Pharmacare, Attridge has made significant contributions to Africa’s healthcare sector.
Apart from his executive and governance roles in Aspen Pharmacare, Attridge owns a notable 4.28-percent stake in Aspen.
Attridge, Aspen’s group chief advisor, who ranks as one of South Africa’s richest businessmen, owns a 4.26-percent stake in the pharmaceutical holding company.
Attridge, Aspen’s group chief advisor, who ranks as one of South Africa’s richest businessmen, owns a 4.26-percent stake in the pharmaceutical holding company.
Attridge, Aspen’s group chief advisor, owns a 4.26-percent stake in the pharmaceutical company.